Virtual Event | Drug Patents and Evidence-Based Policymaking in Patent Law

April 2022

Past Event

Virtual Event | Drug Patents and Evidence-Based Policymaking in Patent Law

Past Event

Online Only

April 15, 2022

Glass medicine bottles on a production line. (Getty Images)

April 2022

Past Event

1201 Pennsylvania Avenue, N.W., Suite 400
Washington, DC 20004

Speakers:

David Kappos

Partner, Cravath, Swaine & Moore LLP, Former Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office

Erika Lietzan

William H. Pittman Professor of Law & Timothy J. Heinsz Professor of Law, University of Missouri School of Law

Adam Mossoff

Chair, Forum for Intellectual Property, and Senior Fellow, Hudson Institute, and Professor of Law, Antonin Scalia Law School, George Mason University

This event will premiere on this page at 10:00 a.m. EDT, Friday, April 15. Register for the event here

Join Hudson Institute Senior Fellow Urška Petrovčič and expert panelists David Kappos, Erika Lietzan, and Senior Fellow Adam Mossoff for a discussion on the role of drug patents as a driver of innovation in healthcare and the importance of evidence-based policymaking in patent law.

Congress and federal agencies have been holding hearings, issuing reports, and considering various policy measures on whether drug patents raise prices in healthcare. These legislative and policy efforts have been driven by reports published by I-MAK of massively high numbers of patents on specific drugs. Yet as a recent Hudson Institute policy memo by Adam Mossoff explains, I-MAK’s patent numbers are unreliable and its private database is unverifiable. Please join our expert panel for a discussion on the policy debate over drug patents and the importance of evidence-based policymaking by Congress and agencies.

June 2026

In-Person Event | Hudson Institute

Growing the DIB: A Conversation with Deputy Assistant Secretary of War James Mismash

Featured Speakers:

Nadia Schadlow

James Mismash

June 2026

In-Person Event | Hudson Institute

Growing the DIB: A Conversation with Deputy Assistant Secretary of War James Mismash

Please join Hudson Institute for a fireside chat between Hudson Senior Fellow Nadia Schadlow and Deputy Assistant Secretary for Industrial Base Growth and Director of the Office of Small Business Programs James Mismash.

Featured Speakers:

Nadia Schadlow

James Mismash

Learn More

June 2026

In-Person Event | Hudson Institute

Saving Ukrainian Children: A Conversation with Maksym Maksymov

Featured Speakers:

Luke Coffey

Maksym Maksymov

Ambassador Olga Stefanishyna

June 2026

In-Person Event | Hudson Institute

Saving Ukrainian Children: A Conversation with Maksym Maksymov

Please join Hudson Institute as it welcomes Maksym Maksymov, head of Bring Kids Back UA, to discuss his organization’s important work.

Featured Speakers:

Luke Coffey

Maksym Maksymov

Ambassador Olga Stefanishyna

Learn More

June 2026

In-Person Event | Hudson Institute

Winning the Innovation Competition

Featured Speakers:

Bryan Clark

Dan Patt

Emil Michael

June 2026

In-Person Event | Hudson Institute

Winning the Innovation Competition

Please join Hudson Institute Senior Fellows Bryan Clark and Dan Patt for a conversation with Under Secretary of War for Research and Engineering Emil Michael about the Department of War’s efforts to bring AI to the battlefield and implement an innovation strategy that makes the most of America’s commercial and government research sectors.

Featured Speakers:

Bryan Clark

Dan Patt

Emil Michael

Learn More

June 2026

In-Person Event | Hudson Institute

The Code as Witness: COVID Origins, Scientific Accountability, and Preventing the Next Pandemic

Featured Speakers:

John P. Walters

Steven Quay

Senator Roger Marshall

David Asher

June 2026

In-Person Event | Hudson Institute

The Code as Witness: COVID Origins, Scientific Accountability, and Preventing the Next Pandemic

Join Hudson as David Asher sits down with Dr. Quay for a fireside chat. Senator Roger Marshall, who has been a leading voice for stronger oversight of high-risk biological research, will open the program by framing the stakes for Congress, national security, and public health.